Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) EBT (2016 - 2026)

Aytu Biopharma has reported EBT over the past 15 years, most recently at -$10.6 million for Q4 2025.

  • Quarterly EBT fell 2870.68% to -$10.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$24.2 million through Dec 2025, down 900.17% year-over-year, with the annual reading at -$13.7 million for FY2025, 32.44% down from the prior year.
  • EBT was -$10.6 million for Q4 2025 at Aytu Biopharma, down from $2.0 million in the prior quarter.
  • Over five years, EBT peaked at $3.8 million in Q1 2025 and troughed at -$53.3 million in Q1 2022.
  • The 5-year median for EBT is -$6.7 million (2022), against an average of -$9.3 million.
  • The largest YoY upside for EBT was 316.07% in 2025 against a maximum downside of 2870.68% in 2025.
  • A 5-year view of EBT shows it stood at -$11.6 million in 2021, then surged by 42.06% to -$6.7 million in 2022, then surged by 120.9% to $1.4 million in 2023, then plummeted by 72.69% to $382000.0 in 2024, then plummeted by 2870.68% to -$10.6 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EBT are -$10.6 million (Q4 2025), $2.0 million (Q3 2025), and -$19.4 million (Q2 2025).